dr. motzer on the tivo-3 trial examining tivozanib in advanced rcc
Published 3 years ago • 192 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
12:49
the tivo-3 study of tivozanib in metastatic renal cell carcinoma
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
1:44
tivo-3: tivozanib hydrochloride vs sorafenib for refractory advanced rcc
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
2:16
dr. robert motzer analyzes overall survival in the tivo-1 study
-
18:04
webinar | mitochondria and lipid droplets in the spotlight: label free imaging of cell metabolism
-
1:28:18
navigating evolving standards of care in rcc: novel targeted and immunotherapy options
-
17:25
intraventricular carv3-team-e t cells in recurrent glioblastoma
-
1:00
dr. vaishampayan on the potential of tivozanib in advanced rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
4:07
tivo-3 results point to tivozanib activity after rcc progression on axitinib | brian rini
-
2:32
dr. robert motzer discusses the safety and efficacy of tivozanib in kidney cancer
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
6:19
asco gu 2013: tivo 1 study shows tivozanib an option for renal cell carcinoma: dr robert motzer
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
2:42
latest from tivo-3: tivozanib for refractory advanced renal cell carcinoma
-
5:46
tivo-1, phase 3 study in advanced kidney cancer
-
4:18
tivozanib for refractory advanced rcc
-
2:07
dr. subbiah on the importance of tivozanib in rcc
-
2:04
sumanta k. pal, md, shares thoughts on the tivo-3 trial from asco gu 2021
-
0:33
rana mckay, md, offers impressions of the tivo-3 study in highly refractory advanced rcc patients